Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
Date:2/14/2012

ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2011.

Key Highlights:

  • Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder).  
  • The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA).  Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.
  • The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013.
  • Vanda recorded fourth quarter 2011 revenue of $8.4 million including royalties of $1.6 million.  Full year 2011 Fanapt® prescriptions, as reported by IMS, exceeded 120,000, compared to approximately 55,000 for 2010.

  • FULL YEAR 2011 REPORTED RESULTSTotal revenues for the full year 2011 were $31.3 million, compared to $35.7 million for 2010.  Full year 2011 revenues included $4.5 million in Fanapt® royalties received from Novartis, as compared to $3.1 million for the prior year.   Both 2011 and 2010 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt® U.S. and Canadian rights.  2010 full year revenues also included $5.8 million in product sales to Novartis and grant revenue.

    Total operating expenses for 2011 were $
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
    2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
    3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
    4. Vanda Presents Phase III Iloperidone Efficacy Data
    5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
    6. Vanda Pharmaceuticals Provides Update on Iloperidone
    7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
    8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
    9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
    10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
    11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
    (Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
    (Date:3/26/2015)... Cardiologists at Beaumont Hospital, Royal ... implant of a device recently approved by the Food ... The Watchman Left Atrial Appendage Closure implant is an ... reduce the risk of stroke. Atrial fibrillation ... than 5 million Americans. Twenty percent of all strokes ...
    Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
    ... BRISBANE, Calif., Sept. 13 InterMune, Inc. (Nasdaq: ... related to the company,s development program for pirfenidone and ... Annual Congress of the European Respiratory Society (ERS), to ... Dan Welch, Chairman, Chief Executive Officer and President of ...
    ... Sept. 13 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
    Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 3Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 4Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 5Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 6Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results 7
    (Date:3/28/2015)... One in three young athletes who undergo ... at the American Orthopaedic Society for Sports Medicine’s ( ... term success of surgery for patients aged 18 years ... 242 patients who underwent ACL reconstruction between 1993 and ... from North Sydney Orthopaedic and Sports Medicine Centre. “Of ...
    (Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
    (Date:3/28/2015)... CA (PRWEB) March 28, 2015 Healthpointe’s ... ear, nose and throat disorders, are now offering ... a common issue which is characterized by the presence ... 1 in 5 people, tinnitus is a prevalent symptom ... and while it is non-fatal, tinnitus can impede a ...
    (Date:3/28/2015)... Plainview, NY (PRWEB) March 28, 2015 ... provider of dietary supplements announces the release of ... MuffinStop™ was shown in two randomized, double-blind, placebo-controlled ... weight and waist and hip size. MuffinStop™ is ... Sphaeranthus indicus and Garcinia mangostana, fused together to ...
    (Date:3/27/2015)... Commack, Long Island, NY (PRWEB) March 27, 2015 ... standardized, objective, cancer-focused training and business criteria for the ... treatments and services to clients who have experienced or ... member of the global Spafinder Wellness 365® Network, will ... on Spafinder.com and recognized as a provider of safe, ...
    Breaking Medicine News(10 mins):Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4
    ... , THURSDAY, Aug. 11 (HealthDay News) -- The HIV ... a high prevalence of AIDS is 10 to 20 times ... government report indicates. Two percent of poor heterosexuals in ... Disease Control and Prevention researchers, analysis of National HIV Behavioral ...
    ... Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) has awarded ... the University Hospitals (UH) Neuromuscular Center in Northeast Ohio. ... in Cleveland, Oh., UH Ahuja Medical Center in Beachwood, ... Oh., and UH Westlake Health Center in Westlake, Oh., ...
    ... According to a study published in ... Society of Hematology (ASH), researchers have reported that administration ... cells from the bone marrow into the blood, is unlikely ... development of abnormalities involving loss or gains of chromosomes that ...
    ... -- There,s no strong evidence that taking aspirin while ... of becoming pregnant, researchers say. Routine use of ... aspirin may improve blood flow to the womb and ... cause pregnancy complications or miscarriage. To ...
    ... Aug. 11 (HealthDay News) -- Symptoms of Alzheimer,s disease ... according to a new study that examined the relationship ... The study included 105 Alzheimer,s patients and 125 dementia-free ... to 75 (young-old) and those 80 and older (very ...
    ... , THURSDAY, Aug. 11 (HealthDay News) -- The ... with a high prevalence of AIDS is 10 to 20 ... government report indicates. Two percent of poor heterosexuals ... for Disease Control and Prevention researchers, analysis of National HIV ...
    Cached Medicine News:Health News:Poor, Urban Heterosexuals at High Risk of HIV: CDC 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 2Health News:Stem cell mobilization therapy found to be safe for bone marrow donors 3Health News:Alzheimer's Harder to Detect in the Very Old 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: